ArticleClinical ophthalmology (Auckland, N.Z.)2018
Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease.
Article in Clinical ophthalmology (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Cationic nanoemulsion vs. 0.15% sodium hyaluronate artificial tears in the healing process following modern surface keratorefractive surgery.European journal of ophthalmology · 2023Trial
- Eyelid margin cleaning using Deep Cleaning Device for the treatment of meibomian gland dysfunction-associated dry eye: a preliminary investigation.Journal of Zhejiang University. Science. BTrial
- Switching from preserved to preservative-free artificial tears and short-term change in dry eye symptoms and signs: a prospective self-controlled clinic cohort.International ophthalmology · 2026Observational
- Assessment and management of dry eye disease in the UK: standardising reality-based best practice.Eye (London, England) · 2026Article
- Efficacy and Safety of Preservative-Free Bimatoprost 0.01% Gel in Patients with Open-Angle Glaucoma and Ocular Hypertension: Results from Two Phase III Randomized Trials.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Management of Dry Eye Disease with Artificial Tears Containing Hyaluronic Acid and Trehalose: A Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Effect of Preserved Versus Preservative-Free Artificial Tears on the Corneal Epithelial Thickness Mapping by MS-39 in Dry Eye Patients.Journal of ophthalmology · 2026Article
- Preservatives in artificial tears: Assessing impact on dry eye symptoms: Findings from 67 951 questionnaire responses-Project FOREVER.Acta ophthalmologica · 2025Article
- Comparative Efficacy of Platelet-Rich Plasma, Autologous Serum, and Artificial Tears in Dry Eye Disease: A Systematic Review and Meta-Analysis.Biomedicines · 2025Review
- Study of dry eye syndrome: Focus on causative factors, treatment modalities, quality of life, and preservatives used in eye drops.Indian journal of ophthalmology · 2023Article
- Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride.Oxidative medicine and cellular longevity · 2020Article
- The effectiveness and safety of moxibustion for dry eye: Protocol for a systematic review.Medicine · 2019Article
- The use of preservatives in dry eye drops.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Improvement of dryness symptoms at the end of the day with artificial tear.Journal of optometryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDry eye disease (DED) is a chronic, multifactorial disease of the ocular surface leading to discomfort, visual disturbance, and tear film instability, with potential damage to the ocular surface.
aimThe aim of this study was to assess the clinical benefit of a switch from preserved to preservative-free artificial tears (ATs) containing hyaluronate in patients with DED. MATERIALS AND
methodsThis is a nationwide, multicenter, noninterventional, and transversal observational survey.
resultsThe mean age was 51.0±15.4 years, ranging from 6 to 96 years. The majority (61.4%) was female. The mean Ocular Surface Disease Index (OSDI) before the switch was surprisingly high at 56.0±23.5, and 73.0% of the patients had superficial punctate keratitis (SPK). The mean duration of use of preserved ATs before the switch was 15.8±12.1 months. OSDI scores and the presence of SPK correlated with the patients' ages but were independent of the duration of treatment with the preserved AT. The patients using ATs containing "soft" or "vanishing" preservatives presented exactly the same clinical pattern (level of OSDI and frequency of SPK) as those using ATs containing classical preservatives such as benzalkonium chloride (BAK). After switching to preservative-free AT containing hyaluronate (Hyabak
conclusionIn patients suffering from DED and treated with a preserved AT, switching to a preservative-free AT provides clinical benefit by decreasing the severity of DED and reducing the prevalence of SPK, even after only 3 weeks of daily use of the preservative-free AT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.